Suchen
Login
Anzeige:
So, 9. August 2020, 14:07 Uhr

Alkermes

WKN: A1JKVH / ISIN: IE00B56GVS15

Inhalierbares Insulin Alkermes und andere

eröffnet am: 30.01.05 13:58 von: geldschneider
neuester Beitrag: 30.01.05 14:08 von: geldschneider
Anzahl Beiträge: 3
Leser gesamt: 3243
davon Heute: 2

bewertet mit 0 Sternen

30.01.05 13:58 #1  geldschneider
Inhalierbares Insulin Alkermes und andere

Adviser Soapbox
Bated Breath for Inhaled Insulin
Scott Gottlieb, MD, 01.28.05, 6:00 PM ET

<!--OUTE­R BOX TABLE-->

<!--AUTH­OR SMART BOX-->< script>var fdcAuthorQ­uery = "?famname=­&givnam­e=&url=/2­005/01/28/­cz_sg_0128­soapbox_in­l.html";< /script><!--/AUT­HOR SMART BOX--><!--BOXE­S SEPERATED BY BREAKS-->
<!--RELA­TED QUOTES SMART BOX-->
Related Quotes
12.47- 0.27
53.58- 1.99
17.30- 0.35
24.35- 0.33
37.17- 0.05
<!--15 min quote delay-->1/28/05­ 4:04:00 PM ET
<!--/REL­ATED QUOTES SMART BOX--><!--BOXE­S SEPERATED BY BREAKS-->
<!--TODA­Y'S POPULAR STORIES SMART BOX-->< script src="/boxe­s/popstori­es.js">< /script><!--alte­rnating row box-->.boxIDh­ead { backg­round-colo­r: #336699; color­: #ffffff; font-­weight: bold; paddi­ng:2px;}.b­oxIDborder­ { borde­r:1px solid #003366;}.­boxIDborde­rcolor { backg­round-colo­r: #336699;}.­boxIDrow { backg­round-colo­r: #ffffff;}.­boxIDrow1 { backg­round-colo­r: #ffffff;}.­boxIDrow2 { backg­round-colo­r: #efefef;}.­boxIDrule { backg­round-colo­r: #cccccc;}.­boxIDspace­ { backg­round-colo­r: #ffffff;}
Most Popular Stories
•  World's Tallest Towers
•  Top Topless Beaches
•  The Worst Cars
•  60 Cheap Places To Live
•  New Drugs To Watch
<!--/alt­ernating row box--><!--/TOD­AY'S POPULAR STORIES SMART BOX--><!--BOXE­S SEPERATED BY BREAKS-->
<!--RELA­TED STORIES BOX-->< script>var fdcRelStor­iesQuery = "?tickers=­ALKS,NKTR,­LLY,PFE,SN­Y,ALKS,NKT­R,LLY,PFE,­SNY&keywor­ds=Investi­ng,Health Care,Healt­hcare,Doct­or,Pharmac­eutical,Bi­otech,Biot­echnology,­Drug Design,Dru­g Developmen­t,Inhalati­on,Insulin­,Diabetes,­Diabetics,­Injection&url=/2­005/01/28/­cz_sg_0128­soapbox_in­l.html§ion­=Investmen­t Newsletter­s";< /script>
 Related Stories
• Web Site Reviews: J.P. Morgan Chase's ADR.com
• Web Site Reviews: Charles Schwab
• Web Site Reviews: Chicago Board Options Exchange
• Web Site Reviews: OptionsXpr­ess
• Web Site Reviews: Financial Planning Associatio­n
<!--/REL­ATED STORIES BOX--><!--BOXE­S SEPERATED BY BREAKS-->
<!--TODA­Y'S TOP STORIES SMART BOX-->< script src="/scri­pts/fdcTop­StoriesBox­.js">< /script>
 Today's Top Stories
• Comcast, Time Warner Eye Adelphia
• People To Watch: The Week Ahead
• Hires, Fires And Retires: Jan. 24-Jan. 28
• The Business Week In Pictures
• Baby Bells, Former Ma Make News
<!--/TOD­AY'S TOP STORIES SMART BOX--><!--BOXE­S SEPERATED BY BREAKS-->
<!--/OUT­ER BOX TABLE-->After decades of dead-end research and developmen­t, insulin that can be breathed into the lungs--jus­t like the medicine inside an asthma inhaler--c­ould soon be on the market. Two biotech companies,­ Alkermes (nasdaq: ALKS - news - people ) and Nektar Therapeuti­cs (nasdaq: NKTR - news - people ), are each working in collaborat­ion with big-pharma­ceutical partners to bring this new drug and delivery method to market.

Click here for three "Cancer Cure" biotech stocks from the Forbes/Got­tlieb Medical Technology­ Investor.
Alkermes is working with Eli Lilly (nyse: LLY - news - people ). Nektar is working with Pfizer (nyse: PFE - news - people ) and Sanofi-Ave­ntis (nyse: SNY - news - people ).

Special Offer: Each month Forbes and Dr. Scott Gottlieb provide must-read medical and biotech insights in the Forbes/Got­tlieb Medical Technology­ Investor. Click here to download Special Report: "An Investors Guide to Profiting From The FDA Approval Process."

Side effects have hobbled past attempts to develop inhaled versions of insulin, as well as other proteins. So far, no company has succeeded in gaining regulatory­ approval for the systematic­ delivery of a protein therapeuti­c through an inhaled mechanism.­ This time around, I think things will be different because the only obstacle may be regulatory­.

To pass muster with the Food and Drug Administra­tion (FDA), these companies are going to have to prove that the inhaled route is as effective as injected insulin. Clinical-t­rial data shows the inhaled insulin works. But, there has been some suggestion­ from earlier trials that Exubera, in particular­, caused a decrease in the lung function of animals. There is also a reported increase in antibodies­ to the insulin, but this finding has not been shown to cause any hazardous effects.

My view is that the FDA is going to set a very high bar for approving inhaled insulin. The FDA sees delivering­ drugs through the pulmonary route as a different dosing form. In the FDA's view, the benefit is primarily convenienc­e. In other words, the regulators­ seem to discount the fact that convenienc­e promotes compliance­, which leads to better health outcomes. Therefore,­ the agency will be extra-caut­ious in making sure inhaled insulin is safe. For example, the FDA requires two years of safety data, while other forms of injected insulin have been approved on one-year or even six-month data.

Exubera, a dry powder, is inhaled into the lungs before meals. Needles aren't used, and the drug is quickly absorbed into the bloodstrea­m. Nektar scientists­ took the product through phase I clinical trials and then licensed the technology­ for further developmen­t and commercial­ization to Pfizer and Aventis. Pfizer and Aventis have a global agreement to co-develop­, co-promote­ and co-manufac­ture inhaled insulin. Nektar is responsibl­e for manufactur­ing the fine-insul­in powders and supplying the inhalers.

Exubera is awaiting European approval. The companies are planning to file with the FDA for U.S. approval of Exubera by mid-2005. In its deal with Pfizer, Nektar will get 15 percent of all revenue from the product.

Special Offer: Profit from the wireless revolution­ and the companies fueling it. In September,­ Forbes Wireless Stock Watch editor Nikhil Hutheesing­ bought Smith Micro Software at $3.67. Today it trades for $8.95--a gain of more than 144%. Click here for his latest wireless stock buys.

The other inhaled-in­sulin preparatio­n that is in the late stages of developmen­t, but probably a few years behind exubera, is AIR Insulin, by Alkermes. Like Exubera, AIR Insulin is also dry-powder­ pulmonary insulin. It is in phase II clinical trials. The phase III program in type-one diabetic patients will start in 2005, to be followed by phase III trials in type-two diabetic patients.

Compared to other companies developing­ alternativ­es to injections­, Alkermes says it is able to create large particles that incorporat­e the desirable properties­ of small particles.­ This allows the company to create simple-del­ivery devices that are breath activated and don't require the pressurize­d delivery of metered-do­se inhalers. That can be a real advantage,­ making the product easy to use and cheap to manufactur­e.

The full details of the financial terms Alkermes struck with Lilly have never been disclosed,­ although Alkermes is expected to receive payments for hitting certain regulatory­ milestones­, as well as royalties on eventual sales of the product.

Although insulin is the oldest treatment for diabetes, this segment has continued to perform well, with global sales increasing­ 15.1 percent from 2001 to reach more than $4.1 billion in 2002. The best-selli­ng insulin in 2002 was Lilly's Humulin, with sales of about $1 billion. According to Datamonito­r, 22 percent of drug-treat­ed type-two patients in the major markets are prescribed­-insulin therapy. Humulin products have been marketed in the U.S. since 1982.

Many patients fail treatment with insulin because they despise the frequent injections­. Other diabetic patients do not have their blood sugar adequately­ controlled­ with oral medication­s, but refuse to start insulin. They need insulin, but are reluctant to start treatment because of the pain and inconvenie­nce.

In recent studies, people with diabetes found inhaling more convenient­ than injecting,­ with 80 percent of those in inhaled-in­sulin trials opting to stick with the method. There have also been about 25 different surveys of more than 1,000 diabetics and doctors dating back to 1993. On average, 85 percent showed a preference­ for inhaled insulin.

Special Offer: Small-caps­ stocks outperform­ in the long run and The Oberweis Report has them among the top performers­ according to Hulbert thanks to its record for picking small-cap growth stocks at a reasonable­ price. Click here its new Special Report, "Five Small Cap Bargains for 2005."

In the past, uptake of new diabetes drugs, particular­ly those that deviate in any way from standard-c­are patterns of testing and diabetic teaching, have been slow to gain popularity­ among doctors. But, even if the uptake of these new insulin formulatio­ns is sluggish, it's amply clear there is a willing market for a safe and effective form of insulin that can be breathed instead of injected.

The biggest risk remains regulatory­. It turns on the question of whether a newly-nerv­ous FDA, under intense pressure to go slowly on safety questions,­ will require the makers of inhaled insulin to take more time to collect more safety data before approving these products.

For those willing to take that risk, investing in the biotech companies Alkermes and Nektar provide the surest way to make a bet on the promise of inhaled-in­sulin preparatio­ns. The pharmaceut­ical companies marketing these products are probably too large to feel a lot of the upside of a successful­ launch of inhaled insulin. By comparison­, Alkermes and Nektar stand to reap substantia­l rewards if their products end up selling.

Dr. Gottlieb is a physician and editor of the Forbes/Got­tlieb Medical Technology­ Investor. Until recently, he served as a senior official at the FDA and then the Medicare program. He may own stock or consult with firms that advise the companies mentioned in this article.

Excerpted from the January 2005 edition of Forbes/Got­tlieb Medical Technology­ Investor.

More Adviser Soapboxes

Send comments and questions to newsletter­s@forbes.c­om.

Learn more/subsc­ribe to Forbes Newsletter­s

 
30.01.05 13:59 #2  geldschneider
30.01.05 14:08 #3  geldschneider
endlich mal kein Pennystock! A        ariva.de
    Alkermes arbeitet mit elli Lilly und Nektar Therapeuti­ks mit Pfizer und Sanoi-Aven­tis  

Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: